Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Bio-equivalent doses of recombinant HCG and recombinant LH during ovarian stimulation result in similar oestradiol output: a randomized controlled study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Alsbjerg, Birgit ; Elbaek, Helle Olesen ; Laursen, Rita Jakubcionyte ; Povlsen, Betina Boel ; Haahr, Thor ; Yding Andersen, Claus ; Humaidan, Peter. / Bio-equivalent doses of recombinant HCG and recombinant LH during ovarian stimulation result in similar oestradiol output : a randomized controlled study. In: Reproductive BioMedicine Online. 2017 ; Vol. 35, No. 2. pp. 232-238.

Bibtex

@article{fe6db455898d461da58caa4a71e3652d,
title = "Bio-equivalent doses of recombinant HCG and recombinant LH during ovarian stimulation result in similar oestradiol output: a randomized controlled study",
abstract = "In nature, HCG is secreted by the implanting embryo from peri-implantation and onwards. In contrast, LH is mandatory for steroidogenesis and follicular development during the follicular phase, working in synergy with FSH. Moreover, LH is mandatory for the function of the corpus luteum. Although LH and HCG bind to the same receptor, significant molecular, structural and functional differences exist, inducing differences in bioactivity. This randomized controlled study compared the effect of recombinant FSH stimulation combined with daily either micro-dose recombinant HCG or recombinant LH supplementation in a 1:1 bioactivity ratio from day 1 of stimulation in a long gonadotrophin releasing hormone agonist down regulation protocol. A total of 100 patients from a public clinic completed the study. The primary end-point was the oestradiol level on the day of ovulation trigger and the median oestradiol level in the HCG supplemented group was 8662 pmol/l versus 9203 pmol/l in the recombinant LH supplemented group; therefore, no significant difference was found. Moreover, no differences were observed in the number of oocytes retrieved or in the live birth rate. We conclude that recombinant HCG and recombinant LH are equally effective in boosting oestradiol synthesis during ovarian stimulation when used in a 1:1 bioactivity ratio.",
keywords = "Journal Article",
author = "Birgit Alsbjerg and Elbaek, {Helle Olesen} and Laursen, {Rita Jakubcionyte} and Povlsen, {Betina Boel} and Thor Haahr and {Yding Andersen}, Claus and Peter Humaidan",
note = "Copyright {\textcopyright} 2017 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.",
year = "2017",
month = aug,
doi = "10.1016/j.rbmo.2017.05.001",
language = "English",
volume = "35",
pages = "232--238",
journal = "Reproductive BioMedicine Online",
issn = "1472-6483",
publisher = "Reproductive Healthcare Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Bio-equivalent doses of recombinant HCG and recombinant LH during ovarian stimulation result in similar oestradiol output

T2 - a randomized controlled study

AU - Alsbjerg, Birgit

AU - Elbaek, Helle Olesen

AU - Laursen, Rita Jakubcionyte

AU - Povlsen, Betina Boel

AU - Haahr, Thor

AU - Yding Andersen, Claus

AU - Humaidan, Peter

N1 - Copyright © 2017 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

PY - 2017/8

Y1 - 2017/8

N2 - In nature, HCG is secreted by the implanting embryo from peri-implantation and onwards. In contrast, LH is mandatory for steroidogenesis and follicular development during the follicular phase, working in synergy with FSH. Moreover, LH is mandatory for the function of the corpus luteum. Although LH and HCG bind to the same receptor, significant molecular, structural and functional differences exist, inducing differences in bioactivity. This randomized controlled study compared the effect of recombinant FSH stimulation combined with daily either micro-dose recombinant HCG or recombinant LH supplementation in a 1:1 bioactivity ratio from day 1 of stimulation in a long gonadotrophin releasing hormone agonist down regulation protocol. A total of 100 patients from a public clinic completed the study. The primary end-point was the oestradiol level on the day of ovulation trigger and the median oestradiol level in the HCG supplemented group was 8662 pmol/l versus 9203 pmol/l in the recombinant LH supplemented group; therefore, no significant difference was found. Moreover, no differences were observed in the number of oocytes retrieved or in the live birth rate. We conclude that recombinant HCG and recombinant LH are equally effective in boosting oestradiol synthesis during ovarian stimulation when used in a 1:1 bioactivity ratio.

AB - In nature, HCG is secreted by the implanting embryo from peri-implantation and onwards. In contrast, LH is mandatory for steroidogenesis and follicular development during the follicular phase, working in synergy with FSH. Moreover, LH is mandatory for the function of the corpus luteum. Although LH and HCG bind to the same receptor, significant molecular, structural and functional differences exist, inducing differences in bioactivity. This randomized controlled study compared the effect of recombinant FSH stimulation combined with daily either micro-dose recombinant HCG or recombinant LH supplementation in a 1:1 bioactivity ratio from day 1 of stimulation in a long gonadotrophin releasing hormone agonist down regulation protocol. A total of 100 patients from a public clinic completed the study. The primary end-point was the oestradiol level on the day of ovulation trigger and the median oestradiol level in the HCG supplemented group was 8662 pmol/l versus 9203 pmol/l in the recombinant LH supplemented group; therefore, no significant difference was found. Moreover, no differences were observed in the number of oocytes retrieved or in the live birth rate. We conclude that recombinant HCG and recombinant LH are equally effective in boosting oestradiol synthesis during ovarian stimulation when used in a 1:1 bioactivity ratio.

KW - Journal Article

U2 - 10.1016/j.rbmo.2017.05.001

DO - 10.1016/j.rbmo.2017.05.001

M3 - Journal article

C2 - 28532660

VL - 35

SP - 232

EP - 238

JO - Reproductive BioMedicine Online

JF - Reproductive BioMedicine Online

SN - 1472-6483

IS - 2

ER -

ID: 51647775